CD155 as an emerging target in tumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD155 (also known as PVR) is an immunoglobulin-like protein frequently overexpressed on tumor cells.
• It promotes tumor cell proliferation, adhesion, invasion, and migration.
• CD155 interacts with immune receptors TIGIT, CD226, and CD96, modulating immune cell function and contributing to tumor immune escape.

Purpose of the Study:

• To review the relationship between tumor surface CD155 and its receptors.
• To discuss how these interactions regulate tumor immune escape.
• To summarize novel therapeutic strategies and clinical trials targeting CD155 and its receptors for cancer immunotherapy.

Main Methods:

• Literature review of studies on CD155 function in cancer.
• Analysis of the molecular interactions between CD155 and immune receptors (TIGIT, CD226, CD96).
• Summary of preclinical and clinical data for CD155-targeted therapies.

Main Results:

• CD155 plays a critical role in promoting tumor progression and immune evasion.
• Inhibition of the CD155/TIGIT pathway demonstrates efficacy in advanced solid malignancies.
• Combination therapies involving CD155/TIGIT inhibition show potential.

Conclusions:

• CD155 is a key target for overcoming tumor immune escape.
• Targeting CD155 and its receptors offers a promising strategy for next-generation cancer immunotherapies.
• Further clinical investigation of CD155-targeted therapies is warranted.